MentionFox
Home › Executive changes › Apellis Pharmaceuticals, Inc.
Leadership changes · APLS · SEC Form 8-K, Item 5.02

Leadership changes at Apellis Pharmaceuticals, Inc. (2026)

Before you join, sell to or invest in Apellis Pharmaceuticals, Inc.

MentionFox check on Apellis Pharmaceuticals, Inc.: no red flags found in 3 sources (checked 14 November 2026). mentionfox.com/c/executive-changes/apellis-pharmaceuticals

Check Apellis Pharmaceuticals, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Apellis Pharmaceuticals, Inc.?

Who joined and who left Apellis Pharmaceuticals, Inc. (APLS)? 3 filings reported from 2026-03-02 to 2026-05-14, each cited to the company's own filing.

As of November 14, 2026, Apellis Pharmaceuticals, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 2, 2026 to May 14, 2026 (Form 8-K, May 14, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Biogen Inc. also filed stake reports on 1 other company ↓

Sell to companies like Apellis Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-05-14
  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-03-31
  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-03-02
Changes3
Latest filing2026-05-14

Apellis Pharmaceuticals, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-02 to 2026-05-14. Every row below is cited to the filing it comes from, and this page adds each new change as Apellis Pharmaceuticals, Inc. files it.

Also on the record for Apellis Pharmaceuticals, Inc.

DateRecordFigureOur pageSource
June 5, 2026Stake report, Schedule 13G/A, by Morgan Stanley—5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by Deep Track Capital, LP3.55% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by RTW Investments, LP2.9% of the class5%+ stakesSource
May 14, 2026Stake report, Schedule 13D/A, by Biogen Inc.—5%+ stakesSource
May 12, 2026Stake report, Schedule 13G, by STATE STREET CORPORATION5.4% of the class5%+ stakesSource
April 7, 2026Stake report, Schedule 13G/A, by Wellington Management Group LLP0.2% of the class5%+ stakesSource
April 6, 2026Stake report, Schedule 13D, by BIOGEN INC.14.2% of the class5%+ stakesSource
March 26, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
February 17, 2026Stake report, Schedule 13G, by RTW Investments, LP6.1% of the class5%+ stakesSource
February 6, 2026Stake report, Schedule 13G, by BlackRock, Inc.10.5% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by EcoR1 Capital, LLC2.7% of the class5%+ stakesSource
November 7, 2025Stake report, Schedule 13G/A, by Wellington Management Group LLP10.9% of the class5%+ stakesSource

Selling to them or working with them? See who runs Apellis Pharmaceuticals, Inc. now and the warning signs.

Watch Apellis Pharmaceuticals, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Apellis Pharmaceuticals, Inc. and the records around it.

Apellis Pharmaceuticals, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Apellis Pharmaceuticals, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Apellis Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Apellis Pharmaceuticals, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    15 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 13 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-05-14Reportednot named in the filing8-K, 2026-05-14
2026-03-31Reportednot named in the filing8-K, 2026-03-31
2026-03-02Reportednot named in the filing8-K, 2026-03-02
Selling to Apellis Pharmaceuticals, Inc.?

New leaders reset buying decisions — get the Full Report on Apellis Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Apellis Pharmaceuticals, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Apellis Pharmaceuticals, Inc., with the record behind each one.

Find candidates like senior executive at Apellis Pharmaceuticals, Inc.

Every change, in the filing's words

Filed 2026-05-14 · 8-K

Reported

Effective as of the Effective Time, Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O'Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.

Also stated in this filing

  • These resignations were tendered as a result of the Merger and were not a result of any disagreement between the Company and the directors on any matter relating to the Company's operations, policies or practices.
  • In accordance with the terms of the Merger Agreement, effective as of the Effective Time, the director of Purchaser as of immediately prior to the Effective Time, Michael Dambach, became the director of the Company.
Filed 2026-03-31 · 8-K

Reported

The Plan will automatically become effective upon, and subject to the occurrence of, the Merger and therefore will automatically terminate if the Merger Agreement is terminated without the consummation of the Merger.

Also stated in this filing

  • On March 30, 2026, the compensation committee of the Company Board approved the Apellis Pharmaceuticals, Inc. Excise Tax Gross-Up Plan (the "Plan"), which provides that "disqualified individuals" of the Company within the meaning of Section 280G of the Internal Revenue Code (including the Company's named executive officers) may become participants under the Plan.
  • Each participant will have a right under the Plan to receive a gross-up payment in the event that any payments or benefits provided to such participant in connection with the Merger become subject to the excise tax pursuant to Section 4999 of the Internal Revenue Code of 1986, as amended.
  • The gross-up payment would generally place the participant in the same after-tax position that the participant would have been in if the excise tax did not apply to the participant, subject to an aggregate $25 million cap in total gross-up payments that may be made to all participants under the Plan.
  • Notwithstanding the foregoing, to the extent a participant's payments or benefits exceed the participant's applicable Section 280G safe harbor amount by 10% or less, the participant will instead receive a reduction of payments and benefits to the extent necessary to cause the payments not to become subject to the excise tax.
Filed 2026-03-02 · 8-K

Reported

Dr. Dolsten has not been appointed to serve on any committees of the Board.

Also stated in this filing

  • On February 27, 2026, the Board of Directors (the "Board") of Apellis Pharmaceuticals, Inc. (the "Company"), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Mikael Dolsten, M.D., Ph.D., to the Board as a Class I director, effective as of March 1, 2026, to serve until the Annual Meeting of Stockholders to be held in 2027 or until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
  • The Board has determined that Dr. Dolsten is "independent" as contemplated by the Nasdaq Stock Market rules.
  • Dr. Dolsten will be compensated in the same manner as the Company's other non-employee directors.
  • Information concerning the current compensation of the Company's directors for their service on the Board and its committees is set forth in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on April 23, 2025.
  • In the event of a change in control of the Company, the vesting schedule of the option and the RSUs will accelerate in full.
  • Pursuant to the terms of this agreement, the Company may be required, among other things, to indemnify Dr. Dolsten for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as a director of the Company.

Tools for this story

Each opens in a new tab, filled in for Apellis Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/apellis-pharmaceuticals
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of Apellis Pharmaceuticals, Inc.?. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/apellis-pharmaceuticals